News | Artificial Intelligence | June 08, 2022

Us2.ai Receives CE Mark and Patent Allowance for Clinical Workflow Using AI-echo with Cardiac Biomarkers

Expanded US Patent and Trademark Office application 17/093,365 includes diagnosis of heart disease based on combined AI analysis of echo images and cardiac biomarkers

Expanded US Patent and Trademark Office application 17/093,365 includes diagnosis of heart disease based on combined AI analysis of echo images and cardiac biomarkers

June 8, 2022 — Us2.ai, a Singapore-based medtech firm backed by, IHH Healthcare, Heal Partners, Sequoia India, EDBI, Pappas Capital and Partech Ventures has received CE Mark clearance for Us2.v1, a completely automated decision support tool for echocardiography. This follows US FDA clearance in 2021 and Health Sciences Authority Singapore clearance in 2022.

Us2.ai is pleased to announce that Us2.v1 is now available for clinical use in UK and across Europe, US, Canada, Australia, New Zealand and Singapore. Us2.v1 is a patented, automated clinical workflow solution that recognizes and analyzes 2-dimensional and Doppler echo images for comprehensive cardiac measurements needed for the diagnosis, prediction and prognosis of heart disease and pulmonary hypertension.

"These approvals for clinical use across Europe, in the UK and in our home country of Singapore will help accelerate the roll out of Us2.v1 as an important support system for cardiologists,” said James Hare, CEO and co-founder of Us2.ai.

“Heart disease is the leading cause of death globally. Us2.v1 creates a complete and fully automated patient report with editable annotations, conclusions and comparisons to international reference guidelines to ensure cardiologists are armed with all the facts to detect heart issues early and with ease,” added James.

Us2.ai has also announced the receipt of a Notice of Allowance, from the US Patent and Trademark Office, with the title: Clinical Workflow to Diagnose Heart Disease Based on Cardiac Biomarker Measurements and AI Recognition of 2D and Doppler Modality Echocardiogram Images.

"This is important because multi-modality AI analytics, combining imaging and circulating biomarkers, is key for precision approaches in cardiology,” said Dr Carolyn Lam, Senior Consultant Cardiologist at National Heart Centre Singapore, Professor at Duke-National University of Singapore and co-founder of Us2.ai.

Us2.v1 automated measurements include 2-dimensional (cardiac volumes, all 4 chambers of the heart), M-mode (e.g. tricuspid annular plane systolic excursion), spectral Doppler (blood flow across all valves, both PW and CW measurements) and tissue Doppler; thus covering the vast majority of standard measurements for adult transthoracic echocardiography recommended by the American Society of Echocardiography, European Association of Cardiovascular Imaging, and British Society of Echocardiography.  Fully automated Us2.v1 measurements were shown to be completely interchangeable with expert human measurements. Furthermore, Us2.v1 measurements were completely reproducible for a given patient study, with image processing/analysis algorithm computation time of approximately two minutes per study.2

For more information: https://us2.ai/

References:

1 Measurements validated at the Brigham & Women’s Hospital:

Left ventricle: DecT, MV-A, MV-Adur, MV-E, e’ lateral, e’ septal, a’ lateral, a’ septal, s’ lateral, s’ septal, LVEDV MOD biplane, LVEF MOD biplane, LVESV MOD biplane, LVSV MOD biplane, IVSd, LVIDd, LVIDs, LVPWd, E/e’ mean

Left atrium: LAESV MOD biplane

Right ventricle: RVIDd

Right atrium: RAa

Tricuspid valve: Tr Vmax

 

2 Total time for interpretation of a study can depend on other factors such as the interpreting physician and preparation for uploading DICOMs for analysis.

Related Content

News | Artificial Heart

April 25, 2022 – There’s no safe way to get a close-up view of the human heart as it goes about its work: you can’t just ...

Home April 25, 2022
Home
News | Artificial Heart

March 28, 2022 — Carmat, the designer and developer of the world’s most advanced total artificial heart, aiming to ...

Home March 28, 2022
Home
News | Artificial Heart

June 18, 2021 – An experimental artificial heart includes an autoregulation control mechanism, or Auto-Mode, that can ...

Home June 23, 2021
Home
News | Artificial Heart

February 10, 2021 - The U.S. Food and Drug Administration (FDA) has granted artificial heart developer Carmat approval ...

Home February 10, 2021
Home
News | Artificial Heart

May 27, 2020 — Carmat, a developer of the of a next generation advanced total artificial heart, announces the first ...

Home May 27, 2020
Home
News | Artificial Heart

March 10, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the SynCardia Systems 50cc temporary Total ...

Home March 10, 2020
Home
News | Artificial Heart

December 11, 2017 — CorInnova Inc. recently announced it was awarded second prize in the “2017 InnoSTARS” life science ...

Home December 11, 2017
Home
News | Artificial Heart

October 27, 2017 — CorInnova Inc. announced it has received notice of allowance of a seminal patent to protect its ...

Home October 27, 2017
Home
News | Artificial Heart

October 26, 2016 — The U.S. Food and Drug Administration (FDA) provided an update and additional information regarding ...

Home October 26, 2016
Home
News | Artificial Heart

August 29, 2016 — SynCardia Systems, manufacturer of the Total Artificial Heart (TAH), announced that the judge ...

Home September 13, 2016
Home
Subscribe Now